DISCOUNT OPTIONSSCHEIN - MODERNA | Market Closed - Boerse Frankfurt Warrants 13:40:27 2024-05-31 EDT | ||
| 1.26 EUR | +10.53% |
|
| 1 month | -26.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.26 | +10.53% |
| 24-05-30 | 1.14 | -5.00% |
| 24-05-29 | 1.2 | +4.35% |
| 24-05-28 | 1.15 | +16.16% |
| 24-05-27 | 0.99 | +2.06% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 01:40 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VD3YZZ |
| ISIN | DE000VD3YZZ7 |
| Date issued | 2024-04-11 |
| Strike | 150 $ |
| Maturity | 2025-03-21 (292 Days) |
| Parity | 10 : 1 |
| Emission price | 1.61 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.86 € |
|---|---|
| Lowest since issue | 0.97 € |
| Spread | 0.01 € |
| Spread % | 0.80% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
- Stock Market
- Certificates
- Certificat
